Eupraxia Pharmaceuticals EPRX
NASDAQ EPRX
$7.64 +0.14 (+1.80%)
As of: Sep 4, 2026 · 1:07 PM EDT

Eupraxia Pharmaceuticals (EPRX) EV to CFO (2024 - 2026)

Analysis

Eupraxia Pharmaceuticals (EPRX) EV to CFO (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.27 Bn 131.42 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.55 Bn 77.56 Bn 3.93 Bn
3 Argenx Se 63.45 Bn 58.27 Bn 1.37 Bn
4 Moderna 57.73 Bn 52.59 Bn 52.00 Mn
5 Revolution Medicines 44.08 Bn 44.08 Bn -
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.14 Bn 31.84 Bn 992.69 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn -
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn
10 Eupraxia Pharmaceuticals 305.07 Mn 305.07 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -9.84
Mar 31, 2026 -14.67
Dec 31, 2025 -22.57
Sep 30, 2025 -26.57
Jun 30, 2025 -22.12
Mar 31, 2025 -14.64
Dec 31, 2024 -13.11
Sep 30, 2024 -6.04
Jun 30, 2024 -5.92